The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some form of talks or contact will be initiated in the coming period I believe (say Q1 2022), dunno with who or to what level, but I would expect some sort of feelers to be out there.
We will hear how they plan the next year to take to clinic, but that doesn't stop any business development.
It was Blackwell and I don't believe DG would have left while talks about the lead asset were underway. It would have been too damaging. I think they had ended at that point, otherwise he would have waited for the discussions to resume when the lockdown eased.
Why don't you take the time and effort to read the posts properly before you start spouting off, Random Chancer?
I think you'll find I didn't say that I thought the pandemic disrupted discussions. I too believe it was more likely an excuse.
Random, DG had left before that statement, it was written by Blackwell.
FX, the companies strategy has been to undertake the inhaler work before business development.
Didn't AB say she was going to establish whether or not there was any chance of a positive outcome from legacy talks?
If she didn't approach them then they must have walked away and never come back once the pandemic eased.
Jay12 oh sorry I mean ForFxsake
The pandemic didnt disrupt discussions it was used as a convienent excuse by DG. Timeline of event certainly proved that!
FX, I'm saying that having more data and evidence that the drug works adds intrinsic value.
You say they have re-established contact, where did you see that?
" it was more the global lockdown that restricted / closed off previous discussions. Then Anne came on board and the focus has been on proving up the inhaler route, adding value to the proposition."
So you think AB upped the asking price then?
If someone was really interested in NXP002 then the pandemic might have slowed down the proceedings but it wouldn't have killed them. So when contact was re-established, do you think AB said "sorry guys, we're doing more stuff so it's going to cost you more"?
Thanks Kane
is now evaluating the durability of the therapy’s anti-fibrotic effects in these rats, with results expected by early 2022.
Earlier this year, Nuformix announced that it would be receiving a U.S. patent for NXP002 and its therapeutic use.
https://pulmonaryfibrosisnews.com/2021/11/29/nuformixs-nxp002-ipf-shows-promise-preclinical-studies/
pulmonary fibrosis news
Nuformix is focused on repurposing medications approved for one health condition — and proven to be safe for human use — to treat scarring-related conditions and cancer, thereby cutting both the costs and time required to develop a safe and effective treatment.
The company uses cocrystal technology to modify the chemical structure of approved compounds without altering their therapeutic potential.
Nuformix’s lead therapy candidate, NXP002, is a new formulation of tranilast, an oral antiallergic medication shown to have anti-scarring effects.
Studies conducted by the U.K.-based company also showed that tranilast reduces lung tissue scarring, or fibrosis, by suppressing the production of extracellular matrix (ECM) proteins. When present in excessive levels, they contribute to IPF. The ECM is the network of proteins and other molecules that surrounds and supports cells in tissues.
“Tranilast is poorly soluble, meaning it is not well absorbed into the body and tissues, and it also has issues regarding systemic toxicity,” Brindley said, adding that NXP002 “shows greater solubility than the original [compound], allowing it to be delivered to the lungs that are the site of action for IPF.”
By delivering NXP002 directly into the lungs, the company anticipates that “a lower dose will be required to produce a pharmacological and therapeutic effect with reduced systemic toxicity compared to oral dosing,” Brindley said.
Previous studies in lab-grown lung tissue collected from IPF patients showed that NXP002 reduced fibrosis and inflammation and that these effects were increased when the therapy was combined with standard IPF treatments — Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib).
Newly announced data concern additional research focused on the feasibility of inhaled delivery and its effects in rats.
First, researchers found that NXP002 could be formulated into a simple and stable solution with properties suitable for inhaled delivery through nebulization, which creates a fine mist of the medication. The new formulation was also able to achieve the right particle size range for lung delivery using off-the-shelf and commonly used nebulizer devices.
These findings supported the feasibility of delivering NXP002 through nebulization, which was then tested in rats. In these animal studies, researchers evaluated the therapy’s pharmacokinetics (movement into, through, and out of the body) and pharmacodynamics (effects on the body) when delivered through nebulization.
Results showed that NXP002 made its way efficiently to the animals’ lungs, achieving significant levels of exposure in that organ while limiting exposure to the rest of the body compared with oral dosing. In addition, inhaled delivery of NXP002 resulted in a dose-dependent reduction in the levels of fibrosis-relevant mediators.
As part of NXP002’s preclinical data package, the company is now evaluating the du
FX, it was more the global lockdown that restricted / closed off previous discussions. Then Anne came on board and the focus has been on proving up the inhaler route, adding value to the proposition.
“ The Group previously announced that negotiations for out-licensing commercial rights for Asia markets were underway. Discussions have continued but the pace of negotiations has been limited as a result of the COVID-19 pandemic situation, closures to key sites in Asia and access to key personnel. When normal trading conditions return, with direct access to key personnel, we hope to continue these and other efforts to derive value from this product for all key world markets. The value of NXP-002 is not just confined to Asia and we intend to assess interest in regions outside Asia with additional parties.”
I still doesn't make sense to me that the Asian partner is no longer interested. The only reason I can think of is that they couldn't agree on price.
If it was either because they didn't think the product could work or they didn't like who they were dealing with, then both of those reasons no longer stand.
Anyone on the board connected to The Times? But want to follow up on the leak this time the ascendency?
I think one of the key takeouts from what I've found is that REDX was valued at ÂŁ50m before AZ came along due to a few months of other interest picking up the sp.
That is what we are lacking at present.... interest from any interested parties, either buying shares in the market or formulating an approach of some kind for an asset or more.
Indeed it was during pre-clinical.
If NFX achieved the same current value as redx then we'd see an sp of circa 21p. And to be fair redx is down off its high of ÂŁ230m mcap, which would transpose to an NFX sp of circa 40p.
It's probably dropped back to 65p now cos we've rocked up :0)
I could just about suffer 65p.
Looks like the action happened before phase 1 commenced as well.
Hope this link works:
https://www.google.co.uk/url?sa=t&source=web&rct=j&url=https://www.redxpharma.com/wp-content/uploads/2018/12/Redx-signs-out-licensing-agreement-with-AstraZeneca.pdf&ved=2ahUKEwjmr8mQib70AhVGUcAKHSHMCvsQFnoECAMQAQ&usg=AOvVaw2gOf6k69YUT4okAJEhfg9T
As a comparison, NFX has often been compared to REDX, with people stating they went from 8p to 100p+. I was curious so had a bit of a look at it.
REDX was hovering around the 6-8p level for ages prior to March 2020, this gave an mcap of around ÂŁ13m.
It was then subject to an attempted bid to buy the company for 15p which fell through, then a subsequent approach which saw the sp up to around the 25-30p level or mcap around ÂŁ50m.
It also secured a loan facility for ÂŁ30m during that time.
It struck an out-license deal for its IPF stream with AstraZeneca in August which propelled the sp up to 65p (ÂŁ125m mcap). The deal comprised an upfront ÂŁ17m and then milestones up to ÂŁ360m.
The sp currently sits at the 65p level once more.